The Oncosearch | Oncotarget

Multipeptide stimulated PBMCs generate T_EM/T_CM for adoptive cell therapy in multiple myeloma Research Paper

Trupti Vardam-Kaur, Latha B. Pathangey, Daniel J. McCormick, P. Leif Bergsagel, Peter A. Cohen, Sandra J. Gendler

Published Aug 27, 2021 · Vol. 12, No. 20 · pp. 2051-2067

Keywords: multiple myeloma, cellular therapy, CD4/CD8 T cells, peptides, immunotherapy

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Anjan Thakurta, William E. Pierceall, Michael D. Amatangelo, Erin Flynt, Amit Agarwal

Published May 19, 2021 · Vol. 12, No. 15 · pp. 1555-1563

Keywords: multiple myeloma, combinations, immunomodulatory agents, apoptosis, protein degradation

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

Flávia Dias Xavier, Fernando Sergio Blumm Ferreira, Rodrigo Martins Abreu

Published Nov 10, 2020 · Vol. 11, No. 47 · pp. 4371-4386

Keywords: healthcare, multiple myeloma, adherence, elderly, refractory/relapsed

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Christie P.M. Verkleij, Kristine A. Frerichs, Marloes Broekmans, Saida Absalah, Patricia W.C. Maas-Bosman, Sandy Kruyswijk, Inger S. Nijhof, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk

Published Oct 24, 2020 · Vol. 11, No. 45 · pp. 4076-4081

Keywords: multiple myeloma, bispecific antibody, immunotherapy, BCMA, CD38

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

Published Oct 7, 2020 · Vol. 11, No. 44 · pp. 3984-3997

Keywords: pan-RAF inhibitor, Bim, FOXO3a, bortezomib, lenalidomide

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

Rod Balhorn, Monique Cosman Balhorn

Published Aug 5, 2020 · Vol. 11, No. 35 · pp. 3315-3349

Keywords: HLA-DR, selective high affinity ligand, SH7139, SH7129, solid cancers

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway Research Paper

Caroline Dafflon, Swann Gaulis, Louise Barys, Karen Kapur, Vanessa Cornacchione, Lina Schukur, Sebastian Bergling, Elisabetta Traggiai, Selina Jansky, Leon Hellmann, Barbara Schacher Engstler, Grainne Kerr, Antoine de Weck, David A. Ruddy, Ulrike Naumann, Frédéric Stauffer, Christoph Gaul, Ying Lin, Eric Billy, Andreas Weiss, Francesco Hofmann, Moriko Ito, Ralph Tiedt

Published Mar 17, 2020 · Vol. 11, No. 11 · pp. 956-968

Keywords: DOT1L, multiple myeloma, epigenetics, histone methylation, unfolded protein response

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor

Published Feb 26, 2020 · Vol. 11, No. 18 · pp. 1576-1589

Keywords: antifolate, multiple myeloma, pralatrexate, biomarker, reduced folate carrier (RFC)

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor

Published Feb 26, 2020

Keywords: antifolate, multiple myeloma, pralatrexate, biomarker, reduced folate carrier (RFC)

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor

Published Feb 26, 2020

Keywords: antifolate, multiple myeloma, pralatrexate, biomarker, reduced folate carrier (RFC)

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21^Cip1 Research Paper

Anna Huo-Chang Mei, Kaity Tung, Jessie Han, Deepak Perumal, Alessandro Laganà, Jonathan Keats, Daniel Auclair, Ajai Chari, Sundar Jagannath, Samir Parekh, Hearn Jay Cho

Published Feb 18, 2020 · Vol. 11, No. 7 · pp. 727-739

Keywords: MAGE-A3, multiple myeloma, apoptosis, cell cycle regulation, DNA repair

Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma Correction

Prahlad V. Raninga, Giovanna Di Trapani, Slavica Vuckovic, Maneet Bhatia, Kathryn F. Tonissen

Published Jan 13, 2020 · Vol. 12, No. 9 · pp. 948-949

Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma Research Paper

Simone Pacini, Marina Montali, Francesco Mazziotta, Claudia P. Schifone, Lucia Macchia, Vittoria Carnicelli, Francesca M. Panvini, Serena Barachini, Laura Notarfranchi, Giovanni Battista Previti, Gabriele Buda, Mario Petrini

Published Nov 26, 2019 · Vol. 10, No. 63 · pp. 6781-6790

Keywords: multiple myeloma, bone marrow microenvironment, angiogenesis, osteogenesis, mesangiogenic progenitor cells

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma Correction

Jingyu Zhu, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Juan Tang, Zubin Zhang, Yuanying Zeng, Biyin Cao, Chunhua Qiao, Hongjian Zhang, Tingjun Hou, Xinliang Mao

Published Nov 15, 2019 · Vol. 10, No. 65 · pp. 7010-7011

Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma Research Paper

Qiang Qiu, Mengyuan Li, Linyu Yang, Minghai Tang, Li Zheng, Fang Wang, Huandi Qiu, Cailing Liang, Ning Li, Dongni Yi, Yuyao Yi, Cong Pan, Shengyong Yang, Lijuan Chen, Yiguo Hu

Published Oct 15, 2019 · Vol. 10, No. 57 · pp. 5993-6005

Keywords: glutaminase1, multiple myeloma, BPTES, cMYC/KRAS12V-transduced plasmacytoma, mouse model

The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer Research Paper

Shiho Fukui, Kazunori Nagasaka, Yuko Miyagawa, Ryoko Kikuchi-Koike, Yoshiko Kawata, Ranka Kanda, Takayuki Ichinose, Takeru Sugihara, Haruko Hiraike, Osamu Wada-Hiraike, Yuko Sasajima, Takuya Ayabe

Published Oct 15, 2019 · Vol. 10, No. 57 · pp. 5932-5948

Keywords: ovarian cancer, bAP15, TGF-β/Smad signaling, UCHL5, apoptosis

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression Research Paper

Nechama Gilad, Hila Zukerman, Marjorie Pick, Moshe E. Gatt

Published Sep 10, 2019 · Vol. 10, No. 52 · pp. 5480-5491

Keywords: multiple myeloma, CD24, microenvironment, cell cycle and apoptosis changes, tumorigenicity

Targeted drug combination therapy design based on driver genes Research Paper

Lilian Zsákai, Anna Sipos, Judit Dobos, Dániel Erős, Csaba Szántai-Kis, Péter Bánhegyi, János Pató, László Őrfi, Zsolt Matula, Gábor Mikala, György Kéri, István Peták, István Vályi-Nagy

Published Sep 3, 2019 · Vol. 10, No. 51 · pp. 5255-5266

Keywords: combination therapy, cancer driver gene, primary culture, small molecule compound, multiple myeloma

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Florentia Dimitriou, Joanna Mangana, Alessandra Curioni-Fontecedro, Markus Rechsteiner, Patrick Turko, Ralph P. Braun, Reinhard Dummer, Phil F. Cheng

Published May 21, 2019 · Vol. 10, No. 36 · pp. 3373-3384

Keywords: melanoma, additional primary tumors, multiple primary tumors, BRAF V600E mutation, papillary thyroid cancer

Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation Research Paper

Deborah Backs, Ilknur Saglam, Claudia Löffler, Sandra Ihne, Caroline Morbach, Susanne Brenner, Christiane Angermann, Georg Ertl, Stefan Frantz, Stefan Störk, Stefan Knop, Gülmisal Güder

Published May 7, 2019 · Vol. 10, No. 34 · pp. 3154-3165

Keywords: cardiovascular risk factors, cardiovascular diseases, multiple myeloma, arterial hypertension, echocardiography

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Multipeptide stimulated PBMCs generate T_EM/T_CM for adoptive cell therapy in multiple myeloma Research Paper

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21^Cip1 Research Paper

Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma Correction

Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma Research Paper

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma Correction

Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma Research Paper

The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer Research Paper

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression Research Paper

Targeted drug combination therapy design based on driver genes Research Paper

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma Research Paper

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma Research Paper

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1 Research Paper

Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma Correction

Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma Research Paper

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma Correction

Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma Research Paper

The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer Research Paper

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression Research Paper

Targeted drug combination therapy design based on driver genes Research Paper

Melanoma patients with additional primary cancers: a single-center retrospective analysis Research Paper

Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation Research Paper

Multipeptide stimulated PBMCs generate T_EM/T_CM for adoptive cell therapy in multiple myeloma Research Paper

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21^Cip1 Research Paper